Compare Sana Biotechnology Inc (SANA) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Materials Select Sector SPDR Fund — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B). The key difference: Materials Select Sector SPDR Fund is far larger — about 9.2× Sana Biotechnology Inc's market cap, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| SANA | XLB | |
|---|---|---|
Market Cap | $836.71M | $7.73B |
Volume | 4,507,444 | 13,681,146 |
Sector | Health | — |
52-Week High | $5.92 | $53.67 |
52-Week Low | $2.68 | $42.23 |
Typical Hold Time | 23 Days | 70 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
XLB trades at $49.43, up 0.92% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets. Recent news highlights materials as a potential 'anti-AI' play but questions near-term valuation after recent rebounds.
Outlook remains cautious given technical weakness and sector cyclicality. Investment opportunity exists for long-term infrastructure exposure, but risks include overconcentration in chemicals and potential earnings volatility. Current levels near support at $49 require monitoring for breakdown confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
